Concepedia

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Harold J. Burstein, Anna Maria Storniolo, Sandra Franco, John Forster, S. Stein, S. D. Rubin, Vanessa Salazar, Kimberly Blackwell

Annals of Oncology · 2008 · 206 citations · 23 references

Concepts

MedicineOncologyPharmacologyBreast OncologyChemotherapyMetastasisBreast Cancer OncologyBreast Cancer PharmacotherapyHer2-positive Breast CancerLocally Advanced Breast CancerMalignant NeoplasmsMetastatic Breast CancerHer2 InhibitorsHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerPhase Ii InvestigationStudy Phase

References

23

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations

Medicine, Genetics, Oncology +14

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri et al. · Journal of Clinical Oncology · 2002 · 1.5K citations

Medicine, Cardiology, Oncology +16

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +14